(MS Journal editorial) Emerging safety issues in alemtuzumab-treated MS patients on: August 02, 2019, 02:55:41 pm #1 An editorial with cautions about Lemtrada--"Emerging safety issues in alemtuzumab-treated MS patients" in Multiple Sclerosis Journal (August 1, 2019):https://journals.sagepub.com/doi/full/10.1177/1352458519851219 Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
